Kontigo Care (KONT.ST) Stock Analysis & AI Equity Report

Medical - Healthcare Information Services SEK Explore free reports

Kontigo Care (KONT.ST) overview

Kontigo Care (KONT.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Kontigo Care reported revenue of SEK 30.2m and operating profit of SEK 0.9m; the year-end share price was 2.56 SEK and market capitalisation was SEK 78.6m. Kontigo Care is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Kontigo Care's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 52.3mFY 2024
Share price2.56 SEKFY 2024 year end
RevenueSEK 30.2mFY 2024
Operating profitSEK 0.9mFY 2024
Net earningsSEK 0.8mFY 2024
Market capitalisationSEK 78.6mFY 2024 year end

Figures updated on 2025-09-29. Data will be refreshed during report generation.

About Kontigo Care

Kontigo Care AB develops digital healthcare services for addiction treatment and workplace substance monitoring. Its main products are the Previct Care platform for remote support in addiction and mental health care, and Previct Safety for real-time drug testing and safer work environments. The company also provides support, technical service, and related care portal functionality.

Generate the Kontigo Care report

Kontigo Care is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Kontigo Care and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.